Pharma major Lupin Ltd. announced that its subsidiary Lupin Pharmaceuticals Inc. had received final approval for its oral contraceptive Kurvelo tablets - Levonorgestrel and Ethinyl Estradiol tablets, USP - 0.15 mg/0.03 mg from the US FDA to market a generic version of Teva Branded Pharmaceuticals Nordette tablets - Levonorgestrel and Ethinyl Estradiol tablets, USP -, 0.15 mg/0.03 mg.
Lupin's Kurvelo tablets are the AB-rated generic equivalent of Teva's Nordette tablets. Kurvelo tablets is a Levonorgestrel and Ethinyl Estradiol combined oral contraceptive indicated for the prevention pf pregnancy in women who elect to use this product as a method of contraception.
The company is marketing its Kurvelo tablets in 21 light orange colored active tablets containing 0.15 mg Levonorgestrel and 0.03 mg Ethinyl Estradoil and seven pink inert tablets (without hormones). This dosage regimen is identical to that of Nordette.
As per IMS MAT June 2012 sales data, Nordette tablets had annual sales of around $59 million in the US.
At the BSE, Lupin closed Thursday's trading at Rs.570.50, down 0.18 percent from the previous close.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.